FineMark National Bank & Trust Purchases 945 Shares of Danaher Co. (NYSE:DHR)

FineMark National Bank & Trust lifted its holdings in Danaher Co. (NYSE:DHR) by 1.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,877 shares of the conglomerate’s stock after acquiring an additional 945 shares during the period. Danaher makes up approximately 0.7% of FineMark National Bank & Trust’s portfolio, making the stock its 29th biggest position. FineMark National Bank & Trust’s holdings in Danaher were worth $19,957,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in DHR. Belpointe Asset Management LLC lifted its position in shares of Danaher by 65.5% during the 2nd quarter. Belpointe Asset Management LLC now owns 8,146 shares of the conglomerate’s stock valued at $2,035,000 after acquiring an additional 3,224 shares during the period. Foundations Investment Advisors LLC grew its stake in Danaher by 6.1% in the second quarter. Foundations Investment Advisors LLC now owns 1,555 shares of the conglomerate’s stock valued at $389,000 after acquiring an additional 90 shares during the period. Simon Quick Advisors LLC increased its holdings in shares of Danaher by 13.3% during the second quarter. Simon Quick Advisors LLC now owns 3,956 shares of the conglomerate’s stock valued at $988,000 after acquiring an additional 464 shares in the last quarter. Cozad Asset Management Inc. raised its position in shares of Danaher by 4.6% during the second quarter. Cozad Asset Management Inc. now owns 2,074 shares of the conglomerate’s stock worth $518,000 after purchasing an additional 92 shares during the period. Finally, Fortis Capital Advisors LLC acquired a new stake in Danaher in the 2nd quarter valued at $839,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by insiders.

Analysts Set New Price Targets

DHR has been the topic of several research reports. Bank of America upped their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. The Goldman Sachs Group increased their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen lifted their target price on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Finally, Evercore ISI lowered their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Stock Up 0.1 %

DHR opened at $264.49 on Thursday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company’s 50-day moving average price is $260.72 and its two-hundred day moving average price is $255.55. The stock has a market cap of $195.90 billion, a price-to-earnings ratio of 44.83, a PEG ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the company earned $2.05 earnings per share. Danaher’s revenue was down 2.9% compared to the same quarter last year. As a group, equities analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.